<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002337</url>
  </required_header>
  <id_info>
    <org_study_id>234B</org_study_id>
    <secondary_id>22-93-252</secondary_id>
    <nct_id>NCT00002337</nct_id>
  </id_info>
  <brief_title>A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease</brief_title>
  <official_title>A Phase I Safety and Tolerability Study of Four Doses of OPC-8212 (Vesnarinone) in Advanced HIV Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka America Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with
      advanced HIV disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fourteen patients per dose level receive vesnarinone at 1 of 4 doses for 12 weeks. At least
      seven patients at a given dose level must have completed 4 weeks of treatment before dose is
      escalated in subsequent patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>56</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vesnarinone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Chemoprophylaxis for Pneumocystis carinii, candida, mycobacteria, and other
             opportunistic infections.

          -  Acyclovir for up to 14 days for acute herpes outbreaks.

        Patients must have:

          -  Documented HIV infection.

          -  CD4 count 50 - 300 cells/mm3.

          -  No active opportunistic infections.

          -  No fever, diarrhea, or Herpes zoster.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Clinically significant current cardiac disease, including patients who exhibit long
             QTC syndrome on EKG screening and who have an abnormal cardiothoracic ratio on chest
             x-ray at baseline.

          -  Active malignancy (other than cutaneous Kaposi's sarcoma or cutaneous basal cell
             carcinoma or in situ carcinoma of the cervix).

        Concurrent Medication:

        Excluded:

          -  Antiretroviral agents, including ddI, ddC, AZT, and d4T.

          -  Immunosuppressive agents.

          -  Investigational HIV drugs/therapies including vaccines.

          -  Interferon or other immunomodulating agents.

          -  Corticosteroids (other than topical).

          -  Hematopoietins.

          -  Megestrol acetate.

          -  Agents known to cause neutropenia.

          -  Trimethoprim/sulfamethoxazole in excess of 160 mg trimethoprim and 800 mg
             sulfamethoxazole thrice weekly.

          -  Cytotoxic chemotherapy.

        Concurrent Treatment:

        Excluded:

          -  Radiation therapy.

        Patients with the following prior conditions are excluded:

          -  Prior history of cardiac disease.

          -  History of agranulocytosis or severe (grade 3 or worse) drug-induced neutropenia or
             documented abnormalities in granulocyte function.

        Prior Medication:

        Excluded:

          -  AZT, ddI, ddC, d4T, or other nucleoside analog antiretroviral therapy within 14 days
             prior to study entry.

          -  Prior cytotoxic chemotherapy.

          -  Acyclovir for herpes prophylaxis within 48 hours prior to study entry.

        Prior Treatment:

        Excluded within 30 days prior to study entry:

          -  Erythropoietin, transfusion, or blood product use.

          -  Radiation therapy (including electron beam irradiation). Active use of illicit drugs
             (specifically cocaine, amyl nitrate, heroin, and other cardioactive agents).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 1996</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>vesnarinone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vesnarinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

